About this trial
Knee osteoarthritis(OA) is a common degenerative joint disease that often leads to knee pain, stiffness, and a decline in quality of life among middle-aged and elderly individuals. Platelet-rich plasma (PRP) is a regenerative treatment method that involves drawing a small amount of the patient's own blood and using centrifugation process to produce PRP. PRP, which is rich in growth factors and anti-inflammatory cytokines, facilitate the repair of damaged tissues and has been used in treating knee OA. Self-repair factor (SRF), an advanced form of PRP, is created using multi-step centrifugation and proprietary processes to increase platelet concentration. This enhancement may offer superior repair efficacy and faster recovery compared to traditional PRP. To explore this potential, we designed a randomized, double-blind, clinical trial to compare the effectiveness of SRF and PRP in treating degenerative knee osteoarthritis.
Eligibility criteria
Qualifiers
Male or female, aged over 20 and under 80.
Consciousness clear and able to communicate.
Unilateral or bilateral osteoarthritis of the knee with symptoms lasting more than 3 months.
X-ray imaging shows mild to moderate knee osteoarthritis (Kellgren-Lawrence grades 1-3).
Disqualifiers
Severe knee osteoarthritis (Kellgren-Lawrence grade 4).
Currently systemic infection.
Received hyaluronic acid or corticosteroid intraarticular injections within the past six months, or received NSAIDs or oral corticosteroid treatment within 7 days prior to treatment.
The treated joint has undergone joint replacement surgery or major surgery.
Trial design
Treatments tested in this trial
- Lyophilized self growth factor
- Platelet-Rich Plasma(PRP)
- Placebo